Daily Bio News Summary — 2026-10-08: Argenx splits the tape, Viatris buys into pain, and a quieter layoff year

Thursday’s harvest at a glance

Twenty-one items cleared the harvest gate today — the 30-day freshness window, a paywall and liveness check on every URL, and a duplicate sweep against the existing archive. The mix came from six sources: PR Newswire’s FDA feed (6), Fierce Biotech (4), Reuters Biopharma (4), Fierce Pharma (3), Pharmaphorum (2) and BioSpace (2).

The day’s shape is unusual. There is no single dominant story; instead the batch splits into three roughly equal blocks — a licensing-and-acquisition cluster, a regulatory and clinical-advance cluster, and a smaller group of setbacks and market signals. One company, Argenx, appears on both sides of the ledger with two unrelated programs.

Argenx’s split day

The most pointed story of the batch is Argenx, which shows up twice with opposite results. In immunology, the company called it quits on a Vyvgart Hytrulo trial in Sjogren’s disease after a futility flag (Fierce Pharma, 2026-10-08). In gastrointestinal disease, the same day’s Fierce Biotech coverage reports an Argenx Phase 2 win in celiac disease for a program the headline values at $2.2 billion, teeing up a pivotal run (Fierce Biotech, 2026-10-08).

Read together, the two items describe a pipeline being triaged in public rather than a franchise in trouble — but the frontmatter alone does not say whether the celiac win offsets the Sjogren’s stop, and nothing in the harvested fields puts a number on either program’s value beyond the headline figure.

Deal-making: three transactions, three shapes

The largest transaction is Viatris’ $1.65 billion purchase of Pacira, which the headline frames as building the buyer’s pain-relief business (Pharmaphorum, 2026-10-08).

Two licensing deals fill out the cluster. Theramex is paying $250 million for rights to Cevira, a drug-device combination for cervical lesions developed by Asieris (Fierce Pharma, 2026-10-08). And Ono Pharmaceutical is paying $80 million for regional rights to three Biohaven IgG degrader programs, including a Phase 3 Graves’ disease asset (Fierce Biotech, 2026-10-08).

The pattern worth noting: two of the three are regional or asset-level rights deals rather than full acquisitions — the kind of transaction that lets a buyer test a mechanism without absorbing an entire company.

Regulatory and clinical advances: six items

Pfizer’s Tukysa has been cleared for earlier use in breast cancer (Pharmaphorum, 2026-10-08) — a label expansion rather than a new approval. Novartis has secured an FDA expansion for Rhapsido covering the two most common forms of chronic hives (Fierce Pharma, 2026-10-07).

On the trial side, Saol Therapeutics completed enrollment in the pivotal Phase III BEACON trial of SL1002 in chronic pain associated with knee osteoarthritis (PR Newswire FDA, 2026-10-08), and Alpheus Medical opened enrollment in a clinical trial of its sonodynamic therapy in butterfly glioblastoma (PR Newswire FDA, 2026-10-08).

Three device and delivery clearances round out the block: Okami Medical received an expanded indication for its LOBO vascular occluder (PR Newswire FDA, 2026-10-07), Sonorous Neurovascular received FDA IDE approval for the first U.S. pivotal trial of its venous sinus stent in pulsatile tinnitus (PR Newswire FDA, 2026-10-07), and CraniUS Therapeutics won a second 510(k) clearance in six weeks plus a U.S. patent for its NeuroPass-3 cranial drug delivery system (PR Newswire FDA, 2026-10-07).

Setbacks and scrutiny

Newron Pharmaceuticals disclosed five deaths in the late-stage trial of its schizophrenia program while an FDA clinical hold remains in place (BioSpace, 2026-10-08) — the most serious item in the batch and the only one involving patient deaths.

At the corporate level, Cadrenal Therapeutics launched a strategic review of its late-stage cardiology pipeline (Fierce Biotech, 2026-10-07). A strategic review is not itself a wind-down, and the headline prescribes no outcome; it is nonetheless the kind of announcement that usually precedes a sale, a spin-out or a narrowed pipeline.

Capital and market signals

Iambic Therapeutics is aiming for a $135 million IPO to push its cancer drugs through the clinic (Fierce Biotech, 2026-10-08) — an AI-driven drug-discovery company choosing to list rather than raise privately.

The macro datapoint cuts the other way: third-quarter biopharma layoffs fell year over year, with 90% fewer employees affected than in the prior-year period (BioSpace, 2026-10-07). Taken with the day’s IPO ambition, the two items describe a labour market that has stopped contracting faster than it has started hiring again.

Patent litigation, vaccines and a weight-loss readout

Three Reuters items close the batch. Moderna lost a US government-license defense in a patent case brought by Northwestern (Reuters Biopharma, 2026-10-01) — a litigation setback whose financial consequences are not stated in the harvested fields. FDA advisers recommended which flu vaccine strains should be used for the 2027 Southern Hemisphere season (Reuters Biopharma, 2026-10-01), the twice-yearly strain-selection step that precedes manufacturers’ production runs. And Regeneron reported that its weight-loss drug halved muscle loss when combined with Novo Nordisk’s semaglutide in a trial (Reuters Biopharma, 2026-10-01) — a combination readout that speaks to the muscle-preservation debate in obesity medicine.

Biogen’s experimental lupus drug showed benefit against skin symptoms (Reuters Biopharma, 2026-10-02) adds one more immunology datapoint to the batch.

What this batch is NOT telling us

• No new molecular-entity approvals. Every regulatory item today is a label expansion, clearance, designation or trial milestone — not a first approval of a new drug.
• No Endpoints News coverage. All of the source’s candidates were gated by its soft paywall, so the batch leans on Fierce, BioSpace, Pharmaphorum and Reuters for the same stories.
• No megadeals. The largest transaction is Viatris’ $1.65 billion Pacira purchase; the rest are asset or regional rights deals.
• No oncology megadata. The day’s cancer items are one trial enrollment and one label expansion, not readouts.
• No European regulatory news — a reversal from recent days, which carried EU enforcement and withdrawal stories.

Reading order

If you have five minutes, read these in order:

1. Argenx’s Sjogren’s stop and celiac win (Fierce Pharma + Fierce Biotech) — the clearest picture of pipeline triage in the batch.
2. Viatris’ $1.65bn Pacira purchase (Pharmaphorum) — the largest transaction of the day.
3. Newron’s five deaths and the standing FDA hold (BioSpace) — the batch’s most serious safety item.
4. Q3 layoffs down 90% year over year (BioSpace) — the macro signal that sits behind every corporate item today.
5. Regeneron’s muscle-loss combination readout (Reuters Biopharma) — a clinically meaningful obesity datapoint.

How to read the underlying articles

Every item above is filed in src/content/news/ with its original sourceUrl, sourceName and pubDate in the frontmatter. Where an item covers a specific company, the file also carries a companyId that links to a profile in src/content/companies/. Nothing in this summary goes beyond those frontmatter fields — no deal values, analyst quotes or readout numbers have been added beyond what the headlines state.

Today’s items

1. Viatris builds in pain relief with $1.65bn Pacira purchase — Pharmaphorum, 2026-10-08
2. Pfizer’s Tukysa greenlit for earlier use in breast cancer — Pharmaphorum, 2026-10-08
3. Theramex and Asieris strike deal for drug-device combo Cevira — Fierce Pharma, 2026-10-08
4. Argenx calls it quits on Vyvgart Hytrulo Sjogren’s disease trial — Fierce Pharma, 2026-10-08
5. Argenx’s phase 2 celiac win tees up pivotal run for $2.2B drug — Fierce Biotech, 2026-10-08
6. Iambic aims for $135M IPO to push cancer drugs through clinic — Fierce Biotech, 2026-10-08
7. Ono pays $80M for local rights to trio of Biohaven IgG degraders — Fierce Biotech, 2026-10-08
8. Newron reveals 5 deaths in late-stage schizophrenia program as FDA maintains hold — BioSpace, 2026-10-08
9. Alpheus Medical opens enrollment in new clinical trial for butterfly glioblastoma — PR Newswire FDA, 2026-10-08
10. Wellysis secures FDA 510(k) clearance for AI-powered ECG analysis software, S-Patch CardioAI — PR Newswire FDA, 2026-10-08
11. Saol Therapeutics announces completion of enrollment in pivotal Phase III BEACON trial of SL1002 for chronic pain related to knee osteoarthritis — PR Newswire FDA, 2026-10-08
12. Okami Medical receives expanded indication for the LOBO vascular occluder — PR Newswire FDA, 2026-10-07
13. Sonorous Neurovascular receives FDA IDE approval for first U.S. pivotal trial of a venous sinus stent to treat pulsatile tinnitus — PR Newswire FDA, 2026-10-07
14. CraniUS Therapeutics secures second FDA 510(k) clearance in six weeks and earns U.S. patent for NeuroPass-3 cranial drug delivery system — PR Newswire FDA, 2026-10-07
15. Novartis expands Rhapsido’s growing reach in chronic hives — Fierce Pharma, 2026-10-07
16. Cadrenal launches strategic review for cardiology pipeline — Fierce Biotech, 2026-10-07
17. Q3 layoffs down YOY, with 90% fewer biopharma employees affected — BioSpace, 2026-10-07
18. Biogen’s experimental lupus drug shows benefit against skin symptoms — Reuters Biopharma, 2026-10-02
19. US FDA advisers recommend flu vaccine strains for 2027 Southern Hemisphere season — Reuters Biopharma, 2026-10-01
20. Moderna loses US government license defense in Northwestern patent case — Reuters Biopharma, 2026-10-01
21. Regeneron weight-loss drug halves muscle loss in combination with Novo’s semaglutide in trial — Reuters Biopharma, 2026-10-01